Titan Pharmaceuticals
TTNP
TTNP was delisted on the 1st of October, 2025.
24 hedge funds and large institutions have $3.55M invested in Titan Pharmaceuticals in 2017 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 1 increasing their positions, 9 reducing their positions, and 14 closing their positions.
0% less ownership
Funds ownership: 0% → 0% (-0%)
31% less funds holding
Funds holding: 35 → 24 (-11)
36% less capital invested
Capital invested by funds: $5.58M → $3.55M (-$2.03M)
79% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 14
89% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 9
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $1K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$279K |
| 2 |
RJFSA
Raymond James Financial Services Advisors
St. Petersburg,
Florida
|
+$24.8K |
| 3 |
TSS
Two Sigma Securities
New York
|
+$24.8K |
| 4 |
CCB
Cutter & Co Brokerage
Ballwin,
Missouri
|
+$18.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$467K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$334K |
| 3 |
Goldman Sachs
New York
|
-$195K |
| 4 |
ECM
Element Capital Management
New York
|
-$156K |
| 5 |
PP
Paloma Partners
Greenwich,
Connecticut
|
-$136K |
TTNP Hedge Fund Activity: Q3 2017 in Review
24 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in Titan Pharmaceuticals (TTNP) for Q3 2017, worth a combined $3.55M — down 36% from $5.58M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of TTNP and 3 opened new positions — a net loss of 11 holders — while 9 trimmed existing stakes and 1 added.
The largest buyer was Renaissance Technologies, adding an estimated $279K. The largest seller was State Street, exiting entirely with an estimated $467K sold.
- 24 institutional investors held Titan Pharmaceuticals (TTNP) as of Q3 2017, down from 35 in Q2 2017.
- Funds reported $3.55M of Titan Pharmaceuticals stock for Q3 2017, down 36% quarter-over-quarter.
- 3 funds opened new Titan Pharmaceuticals positions in Q3 2017 and 14 closed out, a net change of -11 holders.
- The largest Titan Pharmaceuticals buyer in Q3 2017 was Renaissance Technologies, an estimated $279K added.
- The largest Titan Pharmaceuticals seller in Q3 2017 was State Street, an estimated $467K sold.
Based on aggregated 13F filings for Q3 2017.